GS-248 + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Systemic Sclerosis
Conditions
Systemic Sclerosis
Trial Timeline
Dec 29, 2020 → Jun 15, 2022
NCT ID
NCT04744207About GS-248 + Placebo
GS-248 + Placebo is a phase 2 stage product being developed by Gesynta Pharma for Systemic Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT04744207. Target conditions include Systemic Sclerosis.
What happened to similar drugs?
10 of 20 similar drugs in Systemic Sclerosis were approved
Approved (10) Terminated (4) Active (7)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04744207 | Phase 2 | Completed |
| NCT04036227 | Phase 1 | Completed |
Competing Products
20 competing products in Systemic Sclerosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tabalumab Auto-Injector + Tabalumab Prefilled Syringe | Eli Lilly | Phase 3 | 32 |
| Baricitinib + Placebo | Eli Lilly | Phase 2 | 35 |
| MRA(Tocilizumab) + placebo | Chugai Pharmaceutical | Phase 3 | 40 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 40 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 40 |
| DS-7011a + Placebo | Daiichi Sankyo | Phase 1 | 29 |
| DS-7011a + Placebo | Daiichi Sankyo | Phase 1/2 | 32 |
| Bocidelpar + Placebo | Astellas Pharma | Phase 1 | 21 |
| Parenteral micafungin application + Other parenteral antifungal drugs | Astellas Pharma | Pre-clinical | 26 |
| Micafungin | Astellas Pharma | Phase 2 | 35 |
| E6742 | Eisai | Phase 1/2 | 32 |
| KHK4827 | Kyowa Kirin | Phase 1 | 29 |
| KHK4827 + Placebo | Kyowa Kirin | Phase 3 | 40 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 40 |
| Baricitinib + Cyclophosphamide | Eli Lilly | Approved | 47 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 32 |
| LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of Care | Eli Lilly | Phase 3 | 40 |
| LY3361237 + Placebo | Eli Lilly | Phase 2 | 27 |
| LY2127399 + Placebo | Eli Lilly | Phase 3 | 32 |
| LY3361237 + Placebo | Eli Lilly | Phase 1 | 29 |